{"name":"MSD R&D (China) Co., Ltd.","slug":"msd-r-d-china-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPUl9fdHdmLVV0ZGhXbFRqS0s5TTBoUl8wRmlxeWNuUmRoVFh4aThHNDY3R0hpYmRWT05HY3BqSHFqZmtFT1RGRU5zMHk2dWRxd21aX19SZGd5dmNUcmZYSllXZ3ZYd0pqT0dCUFkza2FGSFBkOTd6anE3VkV4MHBuSzFDQ2lxdWFTeGJ5Ty1wRS0tQ08tZGZjSjVB?oc=5","date":"2026-02-03","type":"pipeline","source":"TradingView","summary":"Merck & Co., Inc. 8-K Filing Analysis - TradingView","headline":"Merck & Co., Inc. 8-K Filing Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9hYTFTcmJWblhkS05GTXJEaHFQMUlrUDNXYTRyWHREVVBTUEJLLUZXSF8tNUJ3cGNLNnFyc3kwV2hxZkFZMExiSHV4SUIyOThyYVR4S0dpdjdkUzZHT3NnNVkyRUlLTy1KOWdfRnRrVDRhRWZyektHQTRyel9EZw?oc=5","date":"2025-11-20","type":"pipeline","source":"pharmaphorum","summary":"The importance of globalisation for patient access - pharmaphorum","headline":"The importance of globalisation for patient access","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNdzZ5SEZYN3RpMDZDei1obVRZWXBUajFRYkwyZTlnNy1vN2pIVzJqc1lDd0lSeHlLTW1BYTNwc0VTdVRIeUVUTHNOY2hzcy1aX0g4TGNmLTBsREdGQ0N3alV0LXozWnM4Uk5CRUtFY0NyU1JIUlVXWGhDSUpkRzA1cHVjTDRfTjFUQXVtNWNfVFBXVEtBMDdWMXhXZG16R1dYY2F3U1YxWGVSRTY3bUtmVHR6ZEloMGtrN0FGNUtreFRfQlVjQzZaa3hJUC1xWVV3bXJ6VmZUREtlSnVnRFZwVG5VZ2RHM2FLajFzd1RwcHl1TGxSNndGMGJyRWRHWXdublcyLVBXN1REdFR1Skw2d1IwYUNoNzA1VENDdG92cnNBemdDTWI1OWdR?oc=5","date":"2025-10-11","type":"regulatory","source":"PR Newswire","summary":"Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy - PR Newswire","headline":"Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progressi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1MMjNIdE96REEwYk8tRUJ2OTI3RUlvTElTbmxpNHZXaFF1ZER4aFFkczR1WHVvZ3liVmtZLVhtZFJkRkVYR3doWGgyMjYwQ2VwSmEycmtuRDBkNDB6d0ZZ?oc=5","date":"2025-09-17","type":"pipeline","source":"nature.com","summary":"Pharmaceutical giants pull out of UK: why it matters for global science - nature.com","headline":"Pharmaceutical giants pull out of UK: why it matters for global science","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNUZSamhuWGZ0Nmt4VmJuNTNSRTlKV09lY0pHUDBqYWZTeHVmRV9hVmtscDk2NVJCS21rZ3I2TjZ0S05fS1JiTW9jTk94V2ZldDFSeXdwNEVRZEZCUlNuSEVnY2RWMWV5bng3RU9XUS1rVTExQ29VSm9Zc1UyZ3ZzNEdQb2N0dzJ0RFI2aDdWNnV0bXZCOEY4b3ltSVpwLTA3VXh0R0NpSlE2WmdmTWgxZVlWNGZaeVJNcUVlWGdpbjh6X0k?oc=5","date":"2025-09-11","type":"pipeline","source":"The Guardian","summary":"Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit | Pharmaceuticals industry - The Guardian","headline":"Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit | Pharmaceuticals industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPN3VhSEI2Z1FibFlBVV9OcWlieWtuYUlsWFNkdURxZ3lOcG1pQ3RfVXgyR1d5aVZxUUFSUV9OeU1JZk1NSS0tSVdYbFZ4SDVvYnhZVFFLZEJ4cUFPbGM3MkhKRTRlaTdwcWhVczhuekZaZ3V4eHNWOU9OUXhLb0xxWXpaeC1ycnJsTkFkamFDUWxpOTVIV3dmM0tvRmdkSV9yVE1jeUs5aG4?oc=5","date":"2025-08-18","type":"pipeline","source":"PR Newswire","summary":"KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS - PR Newswire","headline":"KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNTUlOQ0hlTzVNLUlfWWUyN2pGenY5N0xrOGZ3V3diSVBhZVlaSDBndFlWaFlwZUlQZzl5OTRHU2xDX0F1UmpPd1N4cm9kSjdodi1Qa2FXR25Zb1h2X3lFY1Z0T1QteTFZYmhuV2xRZ3dkS0tPX2VlN1htSXFPRjhfRGR0V2h5RmpTUjlOWA?oc=5","date":"2025-07-31","type":"pipeline","source":"Fierce Pharma","summary":"Merck will lay off 6,000, reducing workforce by 8% in cost-cutting purge - Fierce Pharma","headline":"Merck will lay off 6,000, reducing workforce by 8% in cost-cutting purge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9HUVZtbEZaSGVZWjRiM0xzc0x3cUtTQnRYbkpydjlyYS1GYzJoX2t2bXdPTkRHU3ZYUm5pcGw1RFIxWXRmT2xJQU1uR0drX2tyTDlxZENKVXd4U09fa2NfVm56RFRVRk9rSjVxb3NjUzB6dXZzWEJ2dTZSNA?oc=5","date":"2025-07-29","type":"pipeline","source":"pharmaphorum","summary":"MSD trims outlook as it aims to shave $3bn off costs - pharmaphorum","headline":"MSD trims outlook as it aims to shave $3bn off costs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOU1pzRlBYb0JuV2d6bUl4VVdZNjRYZkZZaktidXBnY2pBVFpkZzQ5MERjaHFqbFdFQ3c1U1BTOW5MOGd4QkN4MUpkaktxS0VFVGktVU9OdGh0UHpNR1VNajZsUUI2a3JRSnNYbmVIQkdydXhMNFZqRnI0cXdvSE1weW93?oc=5","date":"2025-04-25","type":"pipeline","source":"pharmaphorum","summary":"MSD has gauged its financial hit from Trump tariffs - pharmaphorum","headline":"MSD has gauged its financial hit from Trump tariffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPQWZSMm9VRTB3UHZVMUpmY2lrLVg3UEw0c3h4NE1DMVpHM2lDTEdPUDIyUlZ2VmkxTERDaTFaMm5HUEZVZTdoNDFCWTAzem10UmNkczE1Ym55WV9YalVjUXdvY2dFQkY3OTVOQnRDV3hXV21LakpUaUxZc3lRYmtUOG1OOWpuY2tHOV9ncVhiRlpGSG1VRGRpVWlBZmc3WlRkZC1WWHdxR2dmYlkyTTVlUlFpSmQ1MjFPbUp5Mw?oc=5","date":"2025-03-25","type":"deal","source":"European Pharmaceutical Review","summary":"MSD to advance investigational Lp(a) inhibitor in nearly $2b deal - European Pharmaceutical Review","headline":"MSD to advance investigational Lp(a) inhibitor in nearly $2b deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxQRVl0LWhzemhlaWVTTnpEd0VsT2NnemdkcU1zM3NNSlRvQktPVTMxMzNJVFJ4NFE2SnRkWnJTNnhzUGs3N29WZFBNUVVGZ0Q3UzBhRFdHSExRTFBfOGo3cjFhSDNhc1JNZ1VnNFI5N29TX0N4WDBrOXJ0MUtabXpBMDhmY0JBRHd6WVM0eEswZ241TnQySUdUZHVYRkJRdEpjeXFaVUl1WUdOZUFXZ3N6bFBBLTdmZ0VWeS1Uak9YRUN3QTIzSjYtMUV1N0hTVl9LbE1MV3JqdWV0RXpLUVVkSmN1LVAycjBuX1hicWlpSUlXZ183M3VvVWlCamdNajlUbFVXM1N2SUFKdlBHRVVjS0dISUxMZEVJVjFLMC1ndm9MQVlGcDNRclIxc1FMdUFFNGJrd0hQRjR6aEhiOGp0bDF2V1dRUkxLN2tfQzFWQQ?oc=5","date":"2025-03-25","type":"deal","source":"Business Wire","summary":"Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. - Business Wire","headline":"Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE0wX2VOa0ppQ0p0R1hTU2VFYno5MnJlcE1faEtTcHA3WUZlZk1CdFVjbDFiVVRqOE5Yc2VGT3hRRFBrY2FKR054eXh5U1RTeEtpR2t2NUZUQ1dka0hhelR0N1lGN2YzYzhuNmFNbE51VzRpVURWbjJMQUE3RDVoQQ?oc=5","date":"2023-09-07","type":"pipeline","source":"China Daily","summary":"MSD boosts localization of pharma R&D - China Daily","headline":"MSD boosts localization of pharma R&D","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}